Published in Proc Natl Acad Sci U S A on December 19, 2005
Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res (2010) 3.16
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal (2013) 2.59
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One (2008) 2.33
Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci (2008) 1.92
Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis (2008) 1.88
Analysis of the assembly profiles for mitochondrial- and nuclear-DNA-encoded subunits into complex I. Mol Cell Biol (2007) 1.82
Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A (2008) 1.61
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.41
The C. elegans Opa1 homologue EAT-3 is essential for resistance to free radicals. PLoS Genet (2008) 1.40
Expression of the yeast NADH dehydrogenase Ndi1 in Drosophila confers increased lifespan independently of dietary restriction. Proc Natl Acad Sci U S A (2010) 1.37
Mitochondrial mechanisms of cell death and neuroprotection in pediatric ischemic and traumatic brain injury. Exp Neurol (2009) 1.31
Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.30
Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27
Nuclear transport, oxidative stress, and neurodegeneration. Int J Clin Exp Pathol (2011) 1.22
Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog Neurobiol (2013) 1.20
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Reactive oxygen species regulation by AIF- and complex I-depleted brain mitochondria. Free Radic Biol Med (2009) 1.17
Convergence and divergence in gene expression among natural populations exposed to pollution. BMC Genomics (2007) 1.14
Successful amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in a rat animal model. PLoS One (2010) 1.13
Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J Proteome Res (2008) 1.09
Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J (2006) 1.09
Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One (2009) 1.09
Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol (2009) 1.04
Programmed cell death in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.04
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta (2013) 1.04
Interplay between bax, reactive oxygen species production, and cardiolipin oxidation during apoptosis. Biochem Biophys Res Commun (2008) 1.03
MPTP mouse models of Parkinson's disease: an update. J Parkinsons Dis (2011) 1.02
Cardiolipin deficiency leads to decreased cardiolipin peroxidation and increased resistance of cells to apoptosis. Free Radic Biol Med (2008) 0.99
The optic nerve: a "mito-window" on mitochondrial neurodegeneration. Mol Cell Neurosci (2012) 0.95
Mitochondrial dysfunction impairs tumor suppressor p53 expression/function. J Biol Chem (2011) 0.95
Redox control of cardiac excitability. Antioxid Redox Signal (2012) 0.94
Elevated P75NTR expression causes death of engrailed-deficient midbrain dopaminergic neurons by Erk1/2 suppression. Neural Dev (2009) 0.94
Association of glycogen synthase kinase-3β with Parkinson's disease (review). Mol Med Rep (2014) 0.94
Cardiolipin: characterization of distinct oxidized molecular species. J Lipid Res (2010) 0.91
Striatal neuroprotection with methylene blue. Neuroscience (2009) 0.90
Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ (2012) 0.90
Chronic ethanol consumption enhances sensitivity to Ca(2+)-mediated opening of the mitochondrial permeability transition pore and increases cyclophilin D in liver. Am J Physiol Gastrointest Liver Physiol (2010) 0.90
14-3-3theta protects against neurotoxicity in a cellular Parkinson's disease model through inhibition of the apoptotic factor Bax. PLoS One (2011) 0.89
Postischemic oxidative stress promotes mitochondrial metabolic failure in neurons and astrocytes. Ann N Y Acad Sci (2008) 0.87
Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis (2010) 0.86
Ginsenoside Rd Protects SH-SY5Y Cells against 1-Methyl-4-phenylpyridinium Induced Injury. Int J Mol Sci (2015) 0.84
Mitochondrial dysfunction in mouse models of Parkinson's disease revealed by transcriptomics and proteomics. J Bioenerg Biomembr (2009) 0.83
Methylenedioxymethamphetamine inhibits mitochondrial complex I activity in mice: a possible mechanism underlying neurotoxicity. Br J Pharmacol (2010) 0.83
DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease. Cell Death Dis (2014) 0.83
Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondria. J Zhejiang Univ Sci B (2006) 0.82
Alteration of mitochondrial function and cell sensitization to death. J Bioenerg Biomembr (2007) 0.82
BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy (2014) 0.81
Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction. Curr Alzheimer Res (2014) 0.81
Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury. BMC Neurosci (2010) 0.80
Mitochondrial Biology and Neurological Diseases. Curr Neuropharmacol (2016) 0.79
Molecular pathways of programmed cell death in experimental Parkinson's disease. Parkinsonism Relat Disord (2008) 0.78
Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett (2015) 0.78
Piperine induces autophagy by enhancing protein phosphotase 2A activity in a rotenone-induced Parkinson's disease model. Oncotarget (2016) 0.78
Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes. Redox Biol (2014) 0.77
In vitro neuroprotective potential of four medicinal plants against rotenone-induced toxicity in SH-SY5Y neuroblastoma cells. BMC Complement Altern Med (2013) 0.77
Spatial distribution of Parkinson's disease mortality in Spain, 1989-1998, as a guide for focused aetiological research or health-care intervention. BMC Public Health (2009) 0.77
Expression of uncoupling protein 3 in mitochondria protects against stress-induced myocardial injury: a proteomic study. Cell Stress Chaperones (2010) 0.76
MicroRNA-7 inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax and Sirt2. Am J Transl Res (2016) 0.76
14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease. Neuroscience (2015) 0.75
Status Epilepticus in Immature Rats Is Associated with Oxidative Stress and Mitochondrial Dysfunction. Front Cell Neurosci (2016) 0.75
Mechanisms of cell death pathway activation following drug-induced inhibition of mitochondrial complex I. Redox Biol (2015) 0.75
Repair, protection and regeneration of peripheral nerve injury. Neural Regen Res (2015) 0.75
Role of Mitochondria in Neonatal Hypoxic-Ischemic Brain Injury. J Neurosci Rehabil (2015) 0.75
Valproic Acid Protects Primary Dopamine Neurons from MPP(+)-Induced Neurotoxicity: Involvement of GSK3β Phosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway. Biomed Res Int (2017) 0.75
Riboflavin Has Neuroprotective Potential: Focus on Parkinson's Disease and Migraine. Front Neurol (2017) 0.75
Mitochondrial bioenergetics decay in aging: beneficial effect of melatonin. Cell Mol Life Sci (2017) 0.75
Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol (2017) 0.75
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
The pathophysiology of mitochondrial cell death. Science (2004) 13.87
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science (1988) 11.76
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Mitochondrial control of cell death. Nat Med (2000) 9.17
A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev Cell (2002) 5.45
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res (2004) 3.75
Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A (2002) 3.57
Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol (1989) 3.11
Leber hereditary optic neuropathy: identification of the same mitochondrial ND1 mutation in six pedigrees. Am J Hum Genet (1991) 2.70
A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science (1999) 2.68
Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J (2000) 2.65
Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci (2003) 2.31
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25
The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem (2000) 2.08
In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience (1997) 2.07
Neuronal degeneration and mitochondrial dysfunction. J Clin Invest (2003) 2.00
Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci (2001) 1.64
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 1.62
BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development. Dev Cell (2003) 1.56
Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci (2001) 1.35
Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium. J Biol Chem (2002) 1.30
Lifespan and mitochondrial control of neurodegeneration. Nat Genet (2004) 1.30
Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax. J Neurochem (2002) 1.26
The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta (1999) 1.23
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol (2002) 1.19
An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A (2001) 1.11
The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch Biochem Biophys (1987) 1.06
Suppression of complex I gene expression induces optic neuropathy. Ann Neurol (2003) 0.96
Cytochrome c release from rat brain mitochondria is proportional to the mitochondrial functional deficit: implications for apoptosis and neurodegenerative disease. J Neurochem (2005) 0.89
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci (2007) 7.77
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (2004) 4.81
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A (2008) 3.65
The molecular dissection of mtDNA haplogroup H confirms that the Franco-Cantabrian glacial refuge was a major source for the European gene pool. Am J Hum Genet (2004) 3.51
Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci (2010) 3.38
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain (2007) 3.35
Homotypic fusion of ER membranes requires the dynamin-like GTPase atlastin. Nature (2009) 3.31
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest (2008) 3.23
Mitochondria: the next (neurode)generation. Neuron (2011) 3.06
Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc (2007) 3.00
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 2.91
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet (2005) 2.73
Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci (2010) 2.73
Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem (2009) 2.70
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet (2006) 2.66
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64
Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet (2012) 2.59
OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain (2008) 2.57
Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci (2011) 2.52
Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am J Hum Genet (2007) 2.40
FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol (2011) 2.36
Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol (2014) 2.33
Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci (2003) 2.31
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25
Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch Neurol (2005) 2.17
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A (2012) 2.16
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 2.15
Mitochondrial optic neuropathies: our travels from bench to bedside and back again. Clin Experiment Ophthalmol (2013) 2.14
Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol (2002) 2.13
Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc Natl Acad Sci U S A (2006) 2.10
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem (2005) 2.08
Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy. Brain (2013) 2.08
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.05
ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet (2008) 2.04
Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A (2007) 2.01
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Retinal nerve fiber layer evaluation by optical coherence tomography in unaffected carriers with Leber's hereditary optic neuropathy mutations. Ophthalmology (2005) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. Nature (2012) 1.95
Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci (2008) 1.92
The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci U S A (2006) 1.90
Retinal nerve fiber layer evaluation by optical coherence tomography in Leber's hereditary optic neuropathy. Ophthalmology (2005) 1.88
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.87
Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol (2005) 1.83
Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol (2012) 1.77
Genetic clues to the pathogenesis of Parkinson's disease. Nat Med (2004) 1.76
Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med (2012) 1.75
Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci (2003) 1.74
Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc Natl Acad Sci U S A (2012) 1.74
The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain (2007) 1.73
Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript. Free Radic Biol Med (2006) 1.73
The clinical maze of mitochondrial neurology. Nat Rev Neurol (2013) 1.72
A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet (2009) 1.71
Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet (2005) 1.71
MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr (2004) 1.69
Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis. Hum Mol Genet (2007) 1.67
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1. J Biol Chem (2010) 1.65
The MPTP model of Parkinson's disease. Brain Res Mol Brain Res (2005) 1.60
Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest (2003) 1.60